[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo
DS-8201: Regulatory submission in US for HER2 positive metastatic breast cancer in H1 FY 2019 (Daiichi Sankyo) - Apr 26, 2019 - FY 2018 Results: Regulatory submissions in Japan for HER2 positive metastatic breast cancer in H2 FY 2019, EU in H1 FY 2020 
BLA • European regulatory • Japanese regulatory
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005439/FY2018%20Q4_Presentation%20Material.pdf
 
Apr 26, 2019
 
 
846aec63-7912-4631-9f6e-ed7cc5048e22.jpg